Research progress of chimeric antigen receptor-modified T cell in B cell lymphoma
10.3760/cma.j.issn.1009-9921.2014.10.016
- VernacularTitle:嵌合抗原受体T细胞在B细胞淋巴瘤中的研究进展
- Author:
Zhitao YING
- Publication Type:Journal Article
- Keywords:
Lymphoma,B cell;
Chimeric antigen receptor T cell;
CD19
- From:
Journal of Leukemia & Lymphoma
2014;23(10):629-631
- CountryChina
- Language:Chinese
-
Abstract:
The prognosis of B cell lymphoma has been significantly improved in the rituximab era,but there are also patients who are refractory or relapsed after rituximab-containing treatment.Chimeric antigen receptor T (CAR T) cell is a kind of T cell which is genetically modified to target specific antigen expressed on the lymphoma cell surface.The response rate of CAR T cell in relapsed or refractory B cell lymphoma is inspiring.Anti-CD19 CAR T cell is the most popular cell being tested in clinical studies.This article discussed the present situation of CAR T cell in B cell lymphoma,including the efficacy,toxicity,side effects and open questions existing in this treatment.
